Summary of Purpose
To test the safety and pharmacokinetics of GV150526 in patients with a clinical diagnosis of acute ischemic stroke managed in North American centers.Read More →
The following dates are available for this trial. Trial information last updated on 12 August 2008.
|Start Date||First Received||1st Completion||Completion||Verification||Results|
- Glaxo Wellcome, Research Triangle, NC
Randomized (2:1), double-blind, and placebo controlled involving 33 centers. GAIN 2 (GLYA2005; United States and Canada) was designed to further assess the safety of the highest dose tolerated in GAIN 1.